Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0160 • ACR Convergence 2024
Supplement Use in a Diverse Cohort of Individuals with SLE
Russell Ellyson¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Alameda Health System, Highland Hospital, Oakland, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Supplement use among individuals with SLE is not well-characterized, despite potential effects of some supplements on SLE activity or on treatments for SLE or…
Abstract Number: 0189 • ACR Convergence 2024
Racial Discrimination Among African American Women with and Without Systemic Lupus Erythematosus (SLE)
Jessica Browder¹, Paula Ramos², Diane Kamen², Bethany Wolf², S. Sam Lim³, Lori Ann Ueberroth² and Lusawasra King², ¹Florida State University, Tallahassee, FL, ²Medical University of South Carolina, Charleston, SC, ³Emory University, Atlanta, GA
Background/Purpose: Black or African American women are disproportionately affected by SLE but remain underrepresented in research studies. To further knowledge about this health disparity group,…
Abstract Number: 0324 • ACR Convergence 2024
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Daniel Nunez¹, Jenell Volkov¹, Jason Stadanlick¹, Zachary Vorndran¹, Alexandra Ellis¹, Mallorie Werner¹, Justin Cicarelli¹, Jazmean Williams¹, Fatemeh Nezhad¹, Thomas Furmanak², Quynh Lam¹, Rebecca Estremera¹, Yvonne White¹, Jonathan Hogan¹, Claire Miller¹, Tahseen Mozaffar³, Saira Sheikh⁴, David Chang¹ and Samik Basu¹, ¹Cabaletta Bio, Philadelphia, PA, ²Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, ³The University of California, Irvine, Orange, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 0440 • ACR Convergence 2024
Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus
Jessica English¹, Bethany Wolf² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Women with systemic lupus erythematosus (SLE) have increased rates of pre-term birth, small for gestational age babies, and pre-eclampsia compared to women without a…
Abstract Number: 0616 • ACR Convergence 2024
Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus
Victoria Delk¹, Dulaney Wilson², Gary Gilkeson², Jim Oates² and Diane Kamen², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with the potential to severely diminish patients' quality of life (QoL). SLE disproportionately affects young…
Abstract Number: 0634 • ACR Convergence 2024
Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study
Hyemin Jeong¹, Ji-Hyoun Kang¹, Sung-Eun Choi², Dong-Jin Park³ and Shin-Seok Lee⁴, ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ³Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) is a newly developed tool for assessing disease activity in SLE patients. Despite external validation in diverse…
Abstract Number: 0653 • ACR Convergence 2024
Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes
Pu-Jun Fang¹, Ping Hsuan Kuo² and Chun Chi Lu¹, ¹Tri-service general hospital, Taipei, Taiwan (Republic of China), ²Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with diverse organ involvement, notably affecting the kidneys and nervous system. Lupus nephritis (LN) and neuropsychiatric…
Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Victoria Werth¹, Joseph F. Merola², Qianyun Li³, Weihong Yang³ and Catherine Barbey⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²UT Southwestern Medical Center, Dallas, TX, ³Biogen, Cambridge, MA, ⁴Biogen, Baar, Switzerland
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…
Abstract Number: 0844 • ACR Convergence 2024
Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Sheryl Kluberg¹, Sophie E. Mayer², O’Mareen Spence³, Driss Oraichi⁴, Harry Seifert⁴, Omar Ali³, Huifeng Yun⁴, Andrew L. Simon⁵, Jenice S. Ko⁶, Caroline Hugh⁷, Meg Her⁷, Kathleen Shattuck⁷, Richard Platt⁸, Aziza Jamal-Allial⁹, Djeneba Audrey DJIBO¹⁰, Kimberly Daniels¹¹, Qianli Ma¹², Cheryl N McMahill-Walraven¹⁰, Rachel P. Ogilvie¹³, Kristin Palmsten¹⁴, Mano Selvan¹⁵, Najat Ziyadeh¹⁶, Alexis Ogdie¹⁷ and Michael George¹⁸, ¹Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ²Harvard Pilgrim Health Care Institute, Durham, ³GSK, Rockville, ⁴GSK, Rockville, MD, ⁵Harvard Pilgrim Healthcare Institute, Boston, MA, ⁶Harvard Pilgrim Health Care Ins􀆟tute, Boston, MA, ⁷Harvard Pilgrim Health Care Institute, Boston, MA, ⁸Harvard Pilgrim Health Care Institute / Harvard Medical School, Boston, MA, ⁹Carelon Research, Elevance Health, Newton, ¹⁰CVS Health, Blue Bell, ¹¹Carelon Research, Elevance Health, Wilmington, ¹²Humana Healthcare Research, Inc., Louisville, ¹³Optum, Boston, MA, ¹⁴HealthPartners Institute, Minneapolis, ¹⁵Humana Healthcare Research, Sugar Land, Texas, ¹⁶Optum, Baltimore, MD, ¹⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: The recombinant zoster vaccine (RZV) is US Food and Drug Administration-approved for the prevention of herpes zoster (HZ, shingles) in adults ≥50 years, and…
Abstract Number: 1039 • ACR Convergence 2024
Through the LuCIN Lens: Defining Barriers and Forging Solutions for Lupus Clinical Trials in North America
Brandon Jackson¹, Maria Dall'Era², Saira Sheikh³, Xueting Zhang⁴, Taylor Irons⁵, Jennifer Meriwether⁶, Maya Merrell¹ and Stacie Bell⁷, ¹Lupus Research Alliance / Lupus Therapeutics, Miami, FL, ²UCSF, Corte Madera, CA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Weill Cornell, New York, NY, ⁵Lupus Research Alliance / Lupus Therapeutics, Houston, ⁶Lupus Research Alliance / Lupus Therapeutics, New York, NY, ⁷Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the Lupus Clinical Investigators Network (LuCIN), a network of premier research sites…
Abstract Number: 1258 • ACR Convergence 2024
Investigating Factors Associated with Gaps in Care in Adolescents and Young Adults with Systemic Lupus
Tamar Rubinstein¹, Avni Dave², Terrence Calistro³, Kimberly Rapoza³, Joyce Hui-Yuen⁴, Emily Masi⁵, Shari Salzhauer Berkowitz³, Zanab Mian⁶ and Kathleen Kenney-Riley⁷, ¹Albert Einstein College of Medicine, White Plains, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Mercy University, Dobbs Ferry, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Cohen Children's Medical Center, Floral Park, NY, ⁶Cohen Children's Medical Center, Lake Success, NY, ⁷Albert Einstein College of Medicine, Port Chester, NY
Background/Purpose: Adolescents and young adults (AYA) with systemic lupus (SLE) are at an especially high risk for disengagement in care, a possible cause of the…
Abstract Number: 1285 • ACR Convergence 2024
The Impact of Race and Social Determinants of Health on Patient Reported Outcomes in Pediatric Lupus: A CARRA Registry Study
William Soulsby¹, Rebecca Olveda², Jie He³, Laura Berbert⁴, Edie Weller³, Kamil Barbour⁵, Kurt Greenlund⁵, Laura Schanberg⁶, Emily Von Scheven¹, Aimee Hersh⁷, Mary Beth Son⁸, Joyce Chang⁸ and Andrea Knight⁹, and the CARRA Registry Investigators, ¹University of California, San Francisco, San Francisco, CA, ²Palo Alto Medical Foundation, Dublin, CA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Belmont, MA, ⁵CDC, Alpharetta, GA, ⁶Duke University Medical Center, DURHAM, NC, ⁷University of Utah, Salt Lake City, UT, ⁸Boston Children's Hospital, Brookline, MA, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Minoritized race and social determinants of health (SDoH) are associated with lower achievement of the low lupus disease activity state (LLDAS) and higher cumulative…
Abstract Number: 1498 • ACR Convergence 2024
Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mazen Allouni¹, Muhammad Shamim², Krista Topalsky³ and Omer Pamuk⁴, ¹Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ²University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ³University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: The clinical manifestations and outcomes of systemic lupus erythematosus (SLE) reveal notable gender differences, which may impact treatment strategies and patient outcomes. This meta-analysis…
Abstract Number: 1514 • ACR Convergence 2024
Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Erik Cimé-Aké¹, Guadalupe Lima², Emilio G. Lazarini¹, Sandra Juárez³, Luis Llorente² and Hilda Fragoso-Loyo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Neurology and Psychiatry Department, Mexico City, Mexico
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may result from a chronic pro-inflammatory state in which immunosenescent and exhausted T-lymphocytes could be involved.…
Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Meggan Mackay¹, Catriona Wagner², Ashley Pinckney³, Jeffrey Cohen⁴, Zachary Wallace⁵, Arezou Khosroshahi⁶, Jeffrey Sparks⁷, Sandra Lord⁸, Amit Saxena⁹, Roberto Caricchio¹⁰, Alfred Kim¹¹, Diane Kamen¹², Fotios Koumpouras¹³, Anca Askanase¹⁴, Kenneth Smith¹⁵, Joel Guthridge¹⁵, Susan Macwana¹⁶, Sean McCarthy¹⁷, Matthew Sherman¹⁸, Sanaz Daneshfar Hamrah¹⁹, Maria Veri¹⁹, Kate York²⁰, Sarah Walker²¹, Sandeep Narpala²², Robin Carroll²², Bob Lin²², Leonid Serebryanny²², Adrian McDermott²³, William Barry²¹, Ellen Goldmuntz²⁴, James McNamara²⁵, Sara Tedeschi²⁶, Amit Bar-Or²⁷, Dinesh Khanna²⁸, ACV01 Clinical Study Team¹⁵ and Judith James¹⁵, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Rho, St Louis Park, NC, ⁴Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH, ⁵Massachusetts General Hospital, Newton, MA, ⁶Emory University, Atlanta, GA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁸Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Seattle, WA, ⁹NYU School of Medicine, New York, NY, ¹⁰University of Massachusetts Chan Medical School, Worcester, MA, ¹¹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Medical University of South Carolina, Charleston, SC, ¹³Yale School of Medicine, New Haven, CT, ¹⁴Columbia University Medical Center, New York, NY, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷DAIT/NIAID/NIH, Rockville, MD, ¹⁸DAIT/NIAID/NIH, Washington, DC, ¹⁹Division of Allergy, Immunology, and Transplantation, NIH/NIAID, Bethesda, MD, USA., Bethesda, MD, ²⁰Rho Federal Systems Division, Durham, NC, USA., Durham, NC, ²¹Rho, Durham, NC, ²²Vaccine Research Center, NIH/NIAID, Bethesda, MD, USA, Bethesda, MD, ²³Vaccine Research Center, NIH/NIAID, Bethesda, MD, ²⁴NIAID/ NIH, Washington, DC, ²⁵NIH, Bethesda, MD, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, Philadelphia, PA, ²⁸Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].